Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Epileptic seizure
Acute adrenal crisis
Anaphylactic shock
Severe asthma crisis
Migraines and cluster headaches
Opioid overdose
Rheumatoid arthritis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
Financial releases
Financial releases
Release date
Min
Max
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Apply
2019/12/23
Crossject consolidates its financial structure via €5.7 million convertible bond issue
Read the release
2019/11/21
Structured financing of €2.6 million
Read the release
2019/10/14
Crossject signs a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Defense (DOD)
Read the release
2019/10/11
First-half 2019 results and business update
Read the release
2019/10/11
business up date : Focus on progress during last summer
Read the release
2019/06/18
Commercial agreement with DESITIN Pharma for ZENEO® Midazolam in Germany
Read the release
2019/04/18
End of the conversion of convertible bonds issued in 2018
Read the release
2019/03/15
Crossject - Slideshow Annual results 2018
Read the release
2019/03/13
Financial results 2018
Read the release
2019/03/01
CROSSJECT- Gain of pharmaceutical establishment status
Read the release
Pagination
First page
« First
Previous page
‹ Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Current page
6
Page
7
Page
8
Page
9
Next page
Next ›
Last page
Last »
